COVID antiviral drug Molnupiravir efficacy against hospitalization or death drops to 30% compared to placebo group

The analysis of latest data on efficacy is much less than the previous interim analysis announced by the company which was based on data from 762 participants who were divided into molnupiravir group and the control group.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3rkSxzI
via IFTTT